Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease

J Infect Dis. 2007 Mar 1;195(5):633-44. doi: 10.1086/511307. Epub 2007 Jan 22.

Abstract

Cytomegalovirus (CMV)-seronegative recipients (R(-)) of a liver transplant from CMV-positive donors (D(+)) are at high risk for developing late CMV disease after discontinuation of antiviral prophylaxis. Levels of viremia and CMV-specific interferon (IFN)- gamma -producing CD4(+) and IFN- gamma -producing CD8(+) T cell responses were prospectively measured from discontinuation of antiviral prophylaxis until 1 year after transplantation in 17 consecutive D(+)/R(-) patients. CMV loads of >1000 copies/mL were strongly associated with CMV disease in the 6 symptomatic patients. Despite immunosuppression, broadly diverse T cells specific for CMV lysate or peptide libraries spanning pp65 and immediate early (IE) 1 immunodominant CMV antigens developed in all patients. A vigorous CD8(+) T cell response to pp65 and IE1 antigens characterized the D(+)/R(-) cohort. Unexpectedly, none of these responses were predictive of CMV disease or viremia. No significant lymphopenia or functional impairment of CMV-specific T cells was detected in the symptomatic patients, whose morbidity was resolved after antiviral treatment while measurable CMV immunity was maintained during the 1-year observation period.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / therapeutic use
  • CD4-Positive T-Lymphocytes / cytology
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / metabolism
  • Cohort Studies
  • Cytomegalovirus / physiology
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / immunology*
  • Cytomegalovirus Infections / prevention & control
  • Cytomegalovirus Infections / virology
  • Female
  • Ganciclovir / analogs & derivatives
  • Ganciclovir / therapeutic use
  • Humans
  • Immediate-Early Proteins / metabolism
  • Interferon-gamma / metabolism
  • Liver Transplantation* / immunology
  • Longitudinal Studies
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Phosphoproteins / metabolism
  • Risk Factors
  • Valganciclovir
  • Viral Matrix Proteins / metabolism
  • Viral Proteins / metabolism
  • Viremia

Substances

  • Antiviral Agents
  • IE1 protein, cytomegalovirus
  • Immediate-Early Proteins
  • Phosphoproteins
  • Viral Matrix Proteins
  • Viral Proteins
  • cytomegalovirus matrix protein 65kDa
  • Interferon-gamma
  • Valganciclovir
  • Ganciclovir